We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The U.S. Supreme Court has paved the way for the possibility of drugmakers collecting enhanced damages in patent cases, striking down an appellate standard in a unanimous 8-0 decision. Read More
Xellia Pharmaceuticals and the FDA have agreed on a modified consent decree so Xellia can resume manufacturing at the Bedford, Ohio, site it purchased from Ben Venue Laboratories. Read More
Valeant will pony up at least $54 million to settle Justice Department allegations that one of its subsidiaries paid kickbacks to convince physicians to prescribe more of its products. Read More
Colombia’s Ministry of Health and Social Protection announced its plans to unilaterally cut the price of Novartis’ myeloid leukemia treatment Gleevec after negotiations with the Swiss drugmaker fell through the cracks. Read More
Biopharmaceutical firm Biocad has filed suit against Roche and its Genentech subsidiary over their alleged use of predatory pricing practices in Russia intended to decimate the sales of the Russian drugmaker’s biosimilars. Read More
Citing the nation’s opioid epidemic, the two top members of the Senate Special Committee on Aging have written to five different drugmakers inquiring about their efforts to improve access to opioid rescue drug naloxone. Read More
A district court judge has spared Gilead from paying a hefty sum in damages to Merck over a HCV patent dispute, overturning a March San Jose federal jury ruling. Read More